Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Open and Multiple Ascending Dose Study to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamic Characteristics of XY0206 in Subjects With Chinese Advanced or Metastatic Solid Tumours

Trial Profile

A Phase I Open and Multiple Ascending Dose Study to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamic Characteristics of XY0206 in Subjects With Chinese Advanced or Metastatic Solid Tumours

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2018

At a glance

  • Drugs XY-0206 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Shijiazhuang Yiling Pharmaceutical
  • Most Recent Events

    • 12 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top